Key Highlights

  • Fund: iShares Nasdaq US Biotechnology UCITS ETF — LSE:BTEC
  • Asset class: Equity
  • Approximate fund AUM: about US$1.2 billion
  • Latest reported NAV: approximately US$10.09 on 11 September 2026
  • Latest market price: around US$10.19 on 24 September 2026
  • YTD NAV total return: approximately 21.4% based on the latest September performance data available
  • 1-year NAV total return: approximately 52.5%
  • 3-year annualised NAV return: approximately 20.5%
  • 5-year annualised NAV return: approximately 6.3%
  • Indicative income yield: not a conventional income strategy because the BTEC Share Class is accumulating
  • Holdings: roughly 250+ securities
  • Benchmark: NASDAQ Biotechnology NET Index
  • Expense ratio: 0.35%
  • Main exposure: US biotechnology and pharmaceutical companies
  • Fund structure: Physical, replicated UCITS ETF
  • Domicile: Ireland

What Is iShares Nasdaq US Biotechnology UCITS ETF — LSE:BTEC?

iShares Nasdaq US Biotechnology UCITS ETF is a specialist healthcare ETF designed to provide diversified exposure to biotechnology and pharmaceutical companies listed on Nasdaq. Rather than relying on one or two individual drug developers, LSE:BTEC spreads exposure across a broad basket of companies involved in drug discovery, therapeutics, biotechnology, genomics and related healthcare activities.

The ETF tracks the NASDAQ Biotechnology NET Index, making movements in the underlying biotechnology universe an important driver of performance. The fund is physically replicated, rebalances quarterly and currently has more than 250 holdings.

How Large Is LSE:BTEC?

The fund has expanded significantly in 2026. The latest official data available around September showed approximately US$1.22 billion in total fund assets, with the relevant accumulating share class representing roughly US$1.14 billion at the time of the September reporting date.

That size provides investors with access to a relatively diversified biotechnology portfolio rather than a narrow collection of smaller speculative companies.

What Is the Latest NAV and Total Return?

The latest reported NAV around 11 September was approximately US$10.09, while the ETF's London Market Price was around US$10.19 on 24 September. Market price and NAV can differ because the ETF trades during market hours while NAV is calculated separately.

Performance has been particularly notable during 2026. The latest official performance data showed approximately:

  • YTD: 21.4% based on the 10 September NAV performance reading
  • 1 year annualised: 52.5%
  • 3 years annualised: 20.5%
  • 5 years annualised: 6.3%
  • Since inception annualised: about 8.6%

The 12-month and longer-term figures demonstrate how strongly biotechnology has recovered from previous periods of weakness, although historical returns should not be interpreted as forecasts.

Does LSE:BTEC Offer a Meaningful Dividend Yield?

Income investors should view BTEC differently from a traditional dividend ETF.

The relevant LSE:BTEC share class is accumulating, meaning portfolio income is generally retained and reinvested within the fund rather than paid out as regular cash distributions. Consequently, an ordinary Cash Dividend Yield is not the central attraction of this ETF.

The Investment case is therefore primarily linked to capital growth, biotechnology earnings, drug approvals, clinical developments, M&A activity and valuation changes rather than dependable dividend income.

Which Companies Are Driving LSE:BTEC?

The portfolio is diversified, but its largest positions can still materially influence returns.

Recent holdings data shows significant exposure to:

  • Gilead Sciences
  • Vertex Pharmaceuticals
  • Amgen
  • Regeneron Pharmaceuticals
  • Moderna
  • Revolution Medicines
  • Illumina
  • Alnylam Pharmaceuticals
  • Biogen
  • Roivant Sciences

The five largest positions together account for a substantial portion of the portfolio, while the top ten represent roughly the mid-40% range.

This means LSE:BTEC provides diversification, but investors should still monitor developments affecting its largest holdings.

Which Sectors and Geographies Does LSE:BTEC Cover?

The ETF is highly concentrated by sector. Official portfolio data shows approximately 99.8% exposure to Health Care, with a small residual allocation to cash and/or derivatives.

Geographically, the strategy is overwhelmingly oriented toward the US biotechnology and pharmaceutical market, reflecting its Nasdaq-focused benchmark. This makes US healthcare regulation, FDA decisions, clinical-trial outcomes, pharmaceutical pricing policies and US capital-market conditions particularly important.

For UK investors, there is also a currency consideration because the London listing can trade in USD, while an investor's Base Currency may be GBP.

Why Is Biotechnology Trending Going Into the Next Phase?

Several themes are keeping biotechnology on investor watchlists.

The sector continues to experience a strong pipeline of clinical developments, drug approvals and commercial launches. Recent industry reporting also points to a significant resurgence in biotechnology IPO activity, with 2026 recording more than 25 biotech public-market debuts before additional companies announced plans to list.

At the company level, developments around next-generation obesity treatments, oncology, immunology, rare diseases, gene therapies and precision medicine remain important sector catalysts. Competition in the weight-loss drug market is particularly intense, with major pharmaceutical and biotechnology groups advancing multiple next-generation candidates.

The Nasdaq Biotechnology index itself stood around 7,023 on 24 September 2026, highlighting the importance of the broader biotech index trend for an ETF such as LSE:BTEC.

What Should Investors Watch Going Forward?

For LSE:BTEC, several indicators could become especially important:

  • FDA approvals and regulatory decisions: Positive approvals can improve sentiment across biotechnology, while unexpected setbacks can rapidly affect individual holdings.
  • Clinical-trial results: Phase II and Phase III data can materially change valuations.
  • Obesity and metabolic-health pipelines: Competition around next-generation treatments remains a major industry theme.
  • Oncology innovation: Cancer diagnostics, immunotherapies and targeted treatments remain significant areas of research.
  • Biotech M&A: Large pharmaceutical companies continue to seek pipeline assets, potentially creating valuation catalysts for smaller biotechnology companies.
  • Interest rates: Earlier-stage biotechnology companies can be sensitive to financing conditions because many depend on external Capital before reaching commercial profitability.
  • Drug-pricing policy: Changes in US healthcare policy can influence pharmaceutical and biotechnology valuations.
  • Portfolio concentration: The performance of major positions such as Gilead, Vertex, Amgen, Regeneron and Moderna can have an outsized impact.
  • GBP/USD movements: UK investors holding a USD-denominated exposure also face currency effects.

What Are the Main Risks of LSE:BTEC?

The Diversification offered by BTEC does not eliminate biotechnology-sector risk. Clinical failures, regulatory delays, Patent issues, pricing pressure and unexpected safety concerns can affect individual holdings.

Valuation risk is another consideration. Biotechnology companies can experience substantial share-price movements when expectations around future drug revenues change.

The ETF is also concentrated in one broad industry, so it does not provide the same diversification as a global or multi-sector Equity ETF. Official fund information specifically identifies concentration in sectors, companies, countries and currencies as relevant risks.

What Is the Overall Investor Watchlist for LSE:BTEC?

LSE:BTEC represents a focused way of following the US biotechnology and pharmaceutical market through a diversified portfolio rather than selecting individual drug developers.

The combination of strong recent performance, more than US$1 billion in assets, broad holdings and exposure to major biotechnology companies makes its future trajectory closely linked to drug-development catalysts, healthcare innovation, regulatory decisions, M&A, Earnings and broader Nasdaq biotechnology momentum.

For investors monitoring LSE:BTEC going forward, the key question is less about dividend income and more about whether the underlying biotechnology companies can convert their pipelines, innovation and clinical progress into sustainable earnings and cash flows.